Autophagy facilitates the progression of ERα-positive breast cancer cells to antiestrogen resistance

Patricia V Schoenlein, Sudharsan Periyasamy Thandavan, Julia S. Samaddar, William H. Jackson, John Thomas Barrett

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

A major impediment to the successful treatment of estrogen receptor α (ERα)-positive breast cancer is the development of antiestrogen resistance. Tamoxifen, the most commonly used antiestrogen, exerts its pharmacological action by binding to ERα and blocking the growth-promoting action of estrogen-bound ERα in breast cancer cells. Tamoxifen treatment primarily induces cytostasis (growth arrest) and the surviving breast cancer cells commonly acquire tamoxifen resistance. Numerous clinically-relevant mechanisms of acquired antiestrogen resistance have been identified by in vitro studies. Our recent studies (Mol Cancer Ther 2008; 7:2977-87) now demonstrate that autophagy (also referred to as macroautophagy) is critical to the development of antiestrogen resistance. Under conditions of compromised autophagy, including treatments with pharmacological inhibitors and RNAi targeting of the beclin 1 gene, the cytotoxicity (death-inducing effects) of the antiestrogen 4-hydroxytamoxifen (4-OHT) was significantly increased. 4-OHT is an active metabolite of tamoxifen commonly used for in vitro studies. A step-wise drug selection protocol, using 4-OHT as the selecting drug, established antiestrogen-resistant breast cancer cell lines. Analysis of a representative resistant cell line showed an increased ability of the cells to sustain high levels of antiestrogen-induced autophagy without progression to death. Importantly, blockade of autophagosome function in the 4-OHT-treated, antiestrogen-resistant cells induced a robust death response. These data provide strong evidence that autophagy is a key mechanism of cell survival during antiestrogen challenge and progression to antiestrogen resistance. We discuss the potential benefit of blocking autophagosome function to significantly reduce the emergence of antiestrogen-resistant breast cancer cells.;

Original languageEnglish (US)
Pages (from-to)400-403
Number of pages4
JournalAutophagy
Volume5
Issue number3
DOIs
StatePublished - Apr 1 2009

Fingerprint

Estrogen Receptor Modulators
Autophagy
Estrogen Receptors
Breast Neoplasms
Tamoxifen
Pharmacology
Cell Line
Growth
RNA Interference
Pharmaceutical Preparations
Cell Survival
Estrogens

Keywords

  • Antiestrogen resistance
  • Autophagy
  • ERα positive breast cancer
  • Retinoblastoma protein
  • Tamoxifen

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

Autophagy facilitates the progression of ERα-positive breast cancer cells to antiestrogen resistance. / Schoenlein, Patricia V; Periyasamy Thandavan, Sudharsan; Samaddar, Julia S.; Jackson, William H.; Barrett, John Thomas.

In: Autophagy, Vol. 5, No. 3, 01.04.2009, p. 400-403.

Research output: Contribution to journalArticle

Schoenlein, Patricia V ; Periyasamy Thandavan, Sudharsan ; Samaddar, Julia S. ; Jackson, William H. ; Barrett, John Thomas. / Autophagy facilitates the progression of ERα-positive breast cancer cells to antiestrogen resistance. In: Autophagy. 2009 ; Vol. 5, No. 3. pp. 400-403.
@article{86dbcfdb5bcb487c84383cb08fb60957,
title = "Autophagy facilitates the progression of ERα-positive breast cancer cells to antiestrogen resistance",
abstract = "A major impediment to the successful treatment of estrogen receptor α (ERα)-positive breast cancer is the development of antiestrogen resistance. Tamoxifen, the most commonly used antiestrogen, exerts its pharmacological action by binding to ERα and blocking the growth-promoting action of estrogen-bound ERα in breast cancer cells. Tamoxifen treatment primarily induces cytostasis (growth arrest) and the surviving breast cancer cells commonly acquire tamoxifen resistance. Numerous clinically-relevant mechanisms of acquired antiestrogen resistance have been identified by in vitro studies. Our recent studies (Mol Cancer Ther 2008; 7:2977-87) now demonstrate that autophagy (also referred to as macroautophagy) is critical to the development of antiestrogen resistance. Under conditions of compromised autophagy, including treatments with pharmacological inhibitors and RNAi targeting of the beclin 1 gene, the cytotoxicity (death-inducing effects) of the antiestrogen 4-hydroxytamoxifen (4-OHT) was significantly increased. 4-OHT is an active metabolite of tamoxifen commonly used for in vitro studies. A step-wise drug selection protocol, using 4-OHT as the selecting drug, established antiestrogen-resistant breast cancer cell lines. Analysis of a representative resistant cell line showed an increased ability of the cells to sustain high levels of antiestrogen-induced autophagy without progression to death. Importantly, blockade of autophagosome function in the 4-OHT-treated, antiestrogen-resistant cells induced a robust death response. These data provide strong evidence that autophagy is a key mechanism of cell survival during antiestrogen challenge and progression to antiestrogen resistance. We discuss the potential benefit of blocking autophagosome function to significantly reduce the emergence of antiestrogen-resistant breast cancer cells.;",
keywords = "Antiestrogen resistance, Autophagy, ERα positive breast cancer, Retinoblastoma protein, Tamoxifen",
author = "Schoenlein, {Patricia V} and {Periyasamy Thandavan}, Sudharsan and Samaddar, {Julia S.} and Jackson, {William H.} and Barrett, {John Thomas}",
year = "2009",
month = "4",
day = "1",
doi = "10.4161/auto.5.3.7784",
language = "English (US)",
volume = "5",
pages = "400--403",
journal = "Autophagy",
issn = "1554-8627",
publisher = "Landes Bioscience",
number = "3",

}

TY - JOUR

T1 - Autophagy facilitates the progression of ERα-positive breast cancer cells to antiestrogen resistance

AU - Schoenlein, Patricia V

AU - Periyasamy Thandavan, Sudharsan

AU - Samaddar, Julia S.

AU - Jackson, William H.

AU - Barrett, John Thomas

PY - 2009/4/1

Y1 - 2009/4/1

N2 - A major impediment to the successful treatment of estrogen receptor α (ERα)-positive breast cancer is the development of antiestrogen resistance. Tamoxifen, the most commonly used antiestrogen, exerts its pharmacological action by binding to ERα and blocking the growth-promoting action of estrogen-bound ERα in breast cancer cells. Tamoxifen treatment primarily induces cytostasis (growth arrest) and the surviving breast cancer cells commonly acquire tamoxifen resistance. Numerous clinically-relevant mechanisms of acquired antiestrogen resistance have been identified by in vitro studies. Our recent studies (Mol Cancer Ther 2008; 7:2977-87) now demonstrate that autophagy (also referred to as macroautophagy) is critical to the development of antiestrogen resistance. Under conditions of compromised autophagy, including treatments with pharmacological inhibitors and RNAi targeting of the beclin 1 gene, the cytotoxicity (death-inducing effects) of the antiestrogen 4-hydroxytamoxifen (4-OHT) was significantly increased. 4-OHT is an active metabolite of tamoxifen commonly used for in vitro studies. A step-wise drug selection protocol, using 4-OHT as the selecting drug, established antiestrogen-resistant breast cancer cell lines. Analysis of a representative resistant cell line showed an increased ability of the cells to sustain high levels of antiestrogen-induced autophagy without progression to death. Importantly, blockade of autophagosome function in the 4-OHT-treated, antiestrogen-resistant cells induced a robust death response. These data provide strong evidence that autophagy is a key mechanism of cell survival during antiestrogen challenge and progression to antiestrogen resistance. We discuss the potential benefit of blocking autophagosome function to significantly reduce the emergence of antiestrogen-resistant breast cancer cells.;

AB - A major impediment to the successful treatment of estrogen receptor α (ERα)-positive breast cancer is the development of antiestrogen resistance. Tamoxifen, the most commonly used antiestrogen, exerts its pharmacological action by binding to ERα and blocking the growth-promoting action of estrogen-bound ERα in breast cancer cells. Tamoxifen treatment primarily induces cytostasis (growth arrest) and the surviving breast cancer cells commonly acquire tamoxifen resistance. Numerous clinically-relevant mechanisms of acquired antiestrogen resistance have been identified by in vitro studies. Our recent studies (Mol Cancer Ther 2008; 7:2977-87) now demonstrate that autophagy (also referred to as macroautophagy) is critical to the development of antiestrogen resistance. Under conditions of compromised autophagy, including treatments with pharmacological inhibitors and RNAi targeting of the beclin 1 gene, the cytotoxicity (death-inducing effects) of the antiestrogen 4-hydroxytamoxifen (4-OHT) was significantly increased. 4-OHT is an active metabolite of tamoxifen commonly used for in vitro studies. A step-wise drug selection protocol, using 4-OHT as the selecting drug, established antiestrogen-resistant breast cancer cell lines. Analysis of a representative resistant cell line showed an increased ability of the cells to sustain high levels of antiestrogen-induced autophagy without progression to death. Importantly, blockade of autophagosome function in the 4-OHT-treated, antiestrogen-resistant cells induced a robust death response. These data provide strong evidence that autophagy is a key mechanism of cell survival during antiestrogen challenge and progression to antiestrogen resistance. We discuss the potential benefit of blocking autophagosome function to significantly reduce the emergence of antiestrogen-resistant breast cancer cells.;

KW - Antiestrogen resistance

KW - Autophagy

KW - ERα positive breast cancer

KW - Retinoblastoma protein

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=65249139482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249139482&partnerID=8YFLogxK

U2 - 10.4161/auto.5.3.7784

DO - 10.4161/auto.5.3.7784

M3 - Article

VL - 5

SP - 400

EP - 403

JO - Autophagy

JF - Autophagy

SN - 1554-8627

IS - 3

ER -